CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 39 enrolled
Drug / intervention
TAK-648 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02684396
NCT02684396Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single Oral TAK-648 Doses in Healthy Subjects

Takeda·interventional·Posted Feb 18, 2016·Updated Jul 13, 2016

In Brief

A Phase 1 clinical trial evaluating TAK-648 and TAK-648 Placebo for Healthy Volunteers. Completed, enrolled 39 participants.

Detailed Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of TAK-648 when administered as a single oral dose of TAK-648 solution at escalating dose levels in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 18, 2016
Enrollment StartAug 1, 2014
Primary CompletionApr 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.4 years ago

Interventions

TAK-648drug

TAK-648 Solution

TAK-648 Placebodrug

TAK-648 placebo-matching solution